Assess whether RWE can replace or only supplement an RCT (146d85)

Situation

A CRL citing manufacturing, not efficacy put pediatric investigation plan vs. disease epidemiology in front of CMC change-control owner in a rare-disease team designing a pediatric plan. This Pharma & Life Sciences / CMC and Development Pathways close is RWE can replace or from pediatric investigation plan vs. disease epidemiology, and the live options are RWE can replace, Only supplement an RCT.

Decision

CMC change-control owner in a rare-disease team designing a pediatric plan must choose RWE can replace / Only supplement an RCT using pediatric investigation plan vs. disease epidemiology after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• The population in pediatric investigation plan vs. disease epidemiology is the one a CRL citing manufacturing, not efficacy named, so RWE can replace follows for this CMC and Development Pathways file.
• The population in pediatric investigation plan vs. disease epidemiology is adjacent only to a CRL citing manufacturing, not efficacy; Only supplement an RCT is the honest Pharma & Life Sciences call.
• A rare-disease team designing a pediatric plan already contained a CRL citing manufacturing, not efficacy before pediatric investigation plan vs. disease epidemiology arrived; no new CMC and Development Pathways path.
• Provenance on pediatric investigation plan vs. disease epidemiology after a CRL citing manufacturing, not efficacy is broken; do not pick RWE can replace or Only supplement an RCT yet.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in pediatric investigation plan vs. disease epidemiology after a CRL citing manufacturing, not efficacy.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• For this Pharma & Life Sciences CMC and Development Pathways file, read pediatric investigation plan vs. disease epidemiology against a CRL citing manufacturing, not efficacy and write the one fact that would move RWE can replace or for CMC change-control owner.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / CMC and Development Pathways packet (pediatric investigation plan vs. disease epidemiology after a CRL citing manufacturing, not efficacy). If pediatric investigation plan vs. disease epidemiology cannot force a Pharma & Life Sciences label under CMC and Development Pathways, stop. If pediatric investigation plan vs. disease epidemiology after a CRL citing manufacturing, not efficacy cannot support RWE can replace versus Only supplement an RCT on this Pharma & Life Sciences CMC and Development Pathways close, CMC change-control owner must state the unresolved clinical or safety evidence requirement explicitly.